Thomas Kuhn, Pharm.D., M.B.A.
Chief Executive Officer, Co-Founder
Thomas Kuhn joined Merck KGaA in 2000, where he held various positions in clinical development, largely in the area of diabetes. Between 2004 and 2007, Dr. Kuhn directed global R&D projects, with two products in Phase 2 clinical trials, and life cycle management projects, specifically for Glucophage®, the current reference in diabetes treatment. After the integration of Serono in 2007, he was involved in refining Merck Serono's strategy. With the decision to divest from diabetes as an integrated therapeutic area, Dr. Kuhn drove the project to relocate the diabetes assets, leading to the establishment of Poxel.
Dr. Kuhn holds a Pharmacy degree from the University of Lyon I (France) and an M.B.A. from Ashridge University (UK).
Chief Financial Officer
Prior to joining Poxel, Anne Renevot served as CFO of EOS Imaging where she played a key role in EOS’ successful IPO on Euronext Paris, which raised €39M. At EOS Imaging, Ms. Renevot helped to raise capital through private placements, equity lines and debt offerings. She was responsible for financial regulatory compliance, financial planning and communications, and she also held leading roles in the Company’s acquisitions and partnerships. Before her appointment at EOS Imaging, Ms. Renevot served at Cartier, a luxury goods company, as CFO of Cartier Joaillerie Manufacturing Division and as International Financial Controller. Earlier in her career, Ms. Renevot served as Manager at EY Audit and as a Division Controller at Legris Industries. Anne Renevot received a bachelor’s degree in finance from Audencia Business School in Nantes, France and a master’s degree in corporate finance from Ohio State University, Columbus, Ohio.
Noah D. Beerman, M.B.A.
Executive Vice President, Business Development and President, U.S. Operations
Noah Beerman has been an executive in the biopharmaceutical industry for more than 25 years, beginning at Repligen, Sandoz, Curis, and Technology Management & Funding. Mr. Beerman then joined Indevus Pharmaceuticals, where he was responsible for multiple licensing, co-promotion and M&A agreements, establishing an industry-leading profile in corporate development as Chief Business Officer for the company. Subsequently, he was President, CEO and Director of RXI Pharmaceuticals (now Galena BioPharma), and until 2013 Executive Vice President and Chief Operating Officer at Coronado Biosciences. Most recently, Mr. Beerman has served as an executive consultant in the biopharmaceutical industry, and Director on the Board of Trasir Therapeutics.
Mr. Beerman holds an M.B.A. from Northeastern University's High Technology Program and a Bachelors of Science in Molecular Genetics from the University of Rochester.
Christophe Arbet-Engels, MD, PhD, MBA
Chief Medical Officer, Executive Vice President, Late Development & Medical Affairs
Dr. Arbet-Engels has more than 25 years of experience in life sciences, academia and industry. Dr. Arbet-Engels’ leadership at several large pharmaceutical companies encompasses clinical development and registration, launch and lifecycle management for several innovative drugs for the treatment of diabetes, metabolism and cardiovascular diseases, including Lantus® (insulin glargine) and Jardiance® (empagliflozin). Most recently, he was Vice President, Worldwide Medical, Collaborative Medical Sciences at Biogen, driving strategy and execution of Phase 3b/4 life cycle management activities. Prior to Biogen, Dr. Arbet-Engels worked in senior leadership positions in clinical development and medical affairs at pharmaceutical and biotech companies, including Boehringer Ingelheim, Roche, Merck, Aventis (now Sanofi) and Ligand Pharmaceuticals. In addition, Dr. Arbet-Engels served as a Medical Advisor to MedNest, provided expertise to the Gerson Lehrman Group, and worked as French Foreign Trade Advisor for the French Government to advise and support French or other startup companies develop their business in the U.S. Dr. Arbet-Engels has a medical degree from University of Paris Sud, a PhD in endocrinology/diabetes and metabolism from Paris Descartes University and a master’s degree in business administration from Rutgers University.
Sébastien Bolze, Pharm.D., Ph.D.
Executive Vice President, Non Clinical Development, Co-Founder
Sébastien Bolze has broad experience in drug development from discovery screening to first-in-man clinical trials. Dr. Bolze was global head of the preclinical candidate selection unit at Solvay Pharmaceuticals, a multidisciplinary unit providing support to research projects from optimization of validated hits to delivery of candidates for preclinical development. From 2003 to 2006, he was executive head of the ADME department at Fournier Pharma. He acquired strong organizational and managerial experience in research projects within a multidisciplinary and global environment. Dr. Bolze has also co-authored numerous research publications and posters.
Dr. Bolze is a Pharmacist and holds a Ph.D. in Pharmacokinetics and Drug Metabolism from the University of Lyon I (France).
Sophie Bozec, Ph.D.
Senior Vice President, R&D Pharmacology, Co-Founder
Sophie Bozec joined Merck KGaA in 1998 where she managed a drug discovery team in a pharmacology department. Dr. Bozec has acquired a strong experience for managing research projects from target identification to preclinical development candidates. She has developed her knowledge in models (in vivo and in vitro) used in research programs for identifying preclinical development candidates in the diabetes field. She acquired a solid expertise in metabolic diseases particularly in the diabetes field. This experience in pharmacology led Dr. Bozec to support a clinical development compound for all preclinical pharmacology aspects.
Dr. Bozec holds a Ph.D. in Nutrition, Metabolism and Obesity from the Paris VII University.
Pascale Fouqueray, M.D., Ph.D.
Executive Vice President, Translational Medicine & Early Clinical Development, Co-Founder
Pascale Fouqueray joined Merck KGaA in 2000 from Paris VII University, where she was Assistant Professor of physiology. At Merck KGaA, Dr. Fouqueray's activities were centered on metabolism, with a particular focus on diabetes and obesity but also including lipids and uric acid metabolism. Dr. Fouqueray was responsible for the clinical development of compounds for the treatment of diabetes and gout disease, working on strategies to define and reach proof-of- concept and investigate mechanisms of action.
Dr. Fouqueray graduated from medical school at the University of Angers (France) and then specialized in Endocrinology and Metabolism at the University of Paris V. She holds a Ph.D. from the University of Paris XI.
Senior Vice President, Investor Relations and Public Relations
Ms. Barnes has 20 years of experience in the pharmaceutical and biotechnology industry. Her experience in strategic investor and corporate communications spans the full life cycle of drug development and commercialization. She began her career at Sepracor (now Sunovion Pharmaceuticals; acquired by Dainippon Sumitomo Pharma Co.), a specialty pharmaceutical company, where she held a series of progressively responsible management and executive roles over a 14-year period and most recently served as Senior Vice President, Investor Relations, Corporate Communications and Internal Communications. Ms. Barnes has also served in senior leadership roles at Agenus, an immuno-oncology company and Vision Medicines, an ophthalmology-focused company. Jonae holds a bachelor's degree in political science from Suffolk University and master's degrees in financial economics and multinational commerce from Boston University.